Chinese IVD Firm Annoroad Gene Targets Global Expansion with IPO
China-based Annoroad Gene Technology (Beijing) Co., Ltd. has submitted an initial public offering (IPO) filing...
IPO
Duality Biotherapeutics Clears HKEX Hearing, Set for IPO with $2.7B Valuation
Duality Biotherapeutics, Inc., a biopharmaceutical company focused on developing innovative antibody-drug conjugates (ADCs), has successfully...
Distinct Healthcare Files for Hong Kong IPO to Expand Integrated Medical Services
Shenzhen-based Distinct Healthcare Holdings Limited, a comprehensive medical service provider with integrated online and offline...
PomDoctor Files for Nasdaq IPO to Expand Chronic Disease Management Services
Guangzhou-based PomDoctor Limited, a leading online medical services platform for chronic disease management, has filed...
Visen Pharmaceuticals IPO Launches on Hong Kong Stock Exchange Amid Growth in Endocrine Therapies
China-based Visen Pharmaceuticals, a joint venture between Denmark-headquartered Ascendis Pharma and Vivo Capital, has successfully...
Duality Biotherapeutics Updates IPO Filing with HKSE under Chapter 18A Rules
China-based Duality Biotherapeutics, Inc. updated its initial public offering (IPO) filing to the Hong Kong...
Huge Dental Files for Hong Kong IPO with Diverse Dental Product Portfolio
Shandong-based dental materials company Huge Dental Limited has made an initial public offering (IPO) filing...
Biointron Biologics Files for Public Offering, Aims for BSE Listing
On February 11, Biointron Biologics released its tutoring filing report for the public offering of...
Genuine Biotech Files for Hong Kong IPO with Azvudine and ZS-1003 in Pipeline
China-based Genuine Biotech Limited has filed for an initial public offering (IPO) on the Hong...
Anhui Anke to Invest in Visen Pharma’s Hong Kong IPO as Cornerstone Investor
China – based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced its plan...
Vigonvita Life Sciences Files for IPO on Hong Kong Stock Exchange
Suzhou-based Vigonvita Life Sciences Co., Ltd. has submitted an initial public offering (IPO) filing to...
PegBio’s Lead Product PB-119 Clears HKEX Hearing for Type 2 Diabetes and Obesity Treatment
On January 28, 2025, the Hong Kong Stock Exchange (HKEX) website showed that PegBio Co.,...
Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model
On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita...
Mirxes Holding Files for Hong Kong IPO with Focus on miRNA Test Kits
Mirxes Holding Company Ltd, a Singapore – headquartered RNA technology company, has received a filing...
Ascentage Pharma Prices US IPO at USD 17.25 per ADS
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) has announced the pricing of its initial public...
Shanghai Bao Pharmaceuticals Launches IPO to Advance Biopharmaceutical Pipeline
China-based Shanghai Bao Pharmaceuticals Co., Ltd., a high-end biopharmaceuticals developer, has announced its initial public...
Sichuan Biokin Re-submits IPO Application to Hong Kong Stock Exchange
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) has announced that it has resubmitted its application...
Fujian Haixi Pharmaceuticals Files for Hong Kong IPO
China-based Fujian Haixi Pharmaceuticals Co., Ltd., a commercial-stage innovative pharmaceutical company, has made an initial...
Sepax Technologies Debuts on STAR Market with Soaring IPO Prices
Sino-US firm Sepax Technologies Co., Inc. has successfully completed its initial public offering (IPO) on...
TCMTech Files for IPO on Hong Kong Stock Exchange, Showcasing TCM AI Leadership
China-based TCMTech Inc., recognized as the largest artificial intelligence (AI) empowered traditional Chinese medicine (TCM)...